Meningitis Vaccine Manufacturing: Fermentation Harvest Procedures Affect Purification - Careful analysis of an unusual precipitate identifies defects. - BioPharm International


Meningitis Vaccine Manufacturing: Fermentation Harvest Procedures Affect Purification
Careful analysis of an unusual precipitate identifies defects.

BioPharm International Supplements
Volume 24, Issue 4, pp. s21-s26

Table IV: Fatty acid composition (%) at different stages of processing in lots that precipitated fatty acid.
Analysis of the 300K retentates (see Figure 2, step 4) by GC showed a general trend of lower total fatty acid/GCMP ratios in lots that did not generate precipitation downstream (see Figure 4). No specific level could predict if a lot would precipitate, but 30-40 % (w/w), could be used as an alert level. This interpretation was enhanced when the specific concentration of palmitic acid entering the deacetylation/saponification process was examined. Deacetylations with palmitic acid >0.7 g/l were likely to precipitate (see Table III).

The 300K retentate was the starting material for the saponification reaction. There is a mixture of saturated (palmitic, myristic) and unsaturated (palmitoleic, oleic) fatty acids in this retentate (see Table IV). The precipitate in both the 50K and 30K retentates was composed primarily of sodium palmitate. This contrast is explained by the differences in solubility of the fatty acids. As reported by McBain et al9, the sodium salts of unsaturated fatty acids were more soluble than the sodium salts of saturated fatty acids. Another factor that affects the fatty acid composition of the precipitate is the length of the fatty acid hydrocarbon chain: the longer the hydrocarbon chain, the less soluble the fatty acid was in water. Sodium oleate and sodium laurate are soluble in water at temperatures under 45C. Sodium myristate, palmitate, and stearate have much lower solubility at the same temperature. This property may be the reason for the oleic acid to be the more abundant unsaturated fatty acid in the precipitate, despite the fact that palmitoleic acid is one of the most abundant fatty acid in the 300K retentate.

Since an increase in fatty acid concentration in the 300K retentate was associated with the use of a damaged pump, it is reasonable to conclude that the damaged pump affected the integrity of the cells by increasing shear forces due to metal-to-metal contact. The issue described here highlights the importance of preventive maintenance. The pump had been in place for several years and appeared to work properly, in that it maintained normal flow rates and pressures during operation. Maintenance technicians performed preventive maintenance at routine intervals, focusing on electric current demand and replacing hydraulic oil in the gear case. The pump head was not routinely examined. Given what was learned about the sensitivity of bacterial cells to shear, the authors now visually inspect the pump more often and replace it at any sign of damage.


The authors wish to thank Liqiong Fang, PhD, research scientist, Kirk Ashland, PhD, senior research scientist, Frank Hua, PhD, research scientist, and Catherine Quinn, research associate, all at Baxter Healthcare, Round Lake. IL, who provided critical analyses in support of this study.

AMY ROBINSON, PHD is a senior manager, SHWU-MAAN LEE,* PHD is a technical director, BOB KRUSE, PHD is a research scientist, and PEIFENG HU, PHD is a principal scientist, all at Baxter Healthcare, 8000 Virginia Manor Road, Suite 140. Beltsville, MD 20705.


1. L. Svennerholm, Biochimica et Biophysica Acta, 24, 604-11 (1957).

2. M. Bradford, Anal. Biochem. 72, 248–54 (1976).

3. C.E. Frasch, Production and control of Neisseria meningitidis vaccine, Adv Biotechnol Processes. 13, 123–145 (1990).

4. Microbial Identification by Gas Chromatographic Analysis of Fatty Acid Methyl Esters (GC-FAME), MIDI Technical note #101.

5. E.C. Gotschlich, et. al., J. Biol. Chem. 256, 8915–8921 (1981).

6. V.J. Lewis, R.E. Weaver, and D.G. Hollis, J. Bacteriol. 96, 1–5 (1968).

7. C.W. Moss, et. al., J. Bacteriol. 104, 63–68 (1970).

8. M.M. Rahman, V.S.K. Kolli, C.M. Kahler, G. Shih, D.S. Stephens, and R.W. Carlson, Microbiol. 146, 1901–1911 (2000).

9. J.W. McBain, and W.C. Sierichs, J. Amer. Oil Chemist's Soc. 25, 221–225 (1948).

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here